Doesn’t matter that the endpoints might be different because all treatment in these indications is essentially supportive in nature. Preventing/treating bone mets may extend survival or improve QoL as much as treating the cancer per se (whatever that means).
p.s. The Denosumab phase-3 trial due to report any day has progression-free survival as the primary endpoint.
Market Data 
Markets 
AI
